Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intersect ENT, Inc. - Common Stock (NQ:XENT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, May 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 28.24 (1,000)
Ask (Size) 29.25 (200)
Prev. Close 28.24
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 33,314,586
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Real-World Evidence Study Demonstrates Intersect ENT’s PROPEL® Sinus Implant Reduces Healthcare Resource Utilization
From Intersect ENT, Inc.
Via Business Wire
Intersect ENT Reports Third Quarter 2021 Financial Results
From Intersect ENT, Inc.
Via Business Wire

Performance

More News

Read More
First Implants of PROPEL® Contour in Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery in Europe
From Intersect ENT®, Inc.
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, LMRK, XENT, JAX; Shareholders are Encouraged to Contact the Firm
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
Exposures Legal
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates INOV, GTS, XONE, XENT; Shareholders are Encouraged to Contact the Firm
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
Exposures Legal
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates CSOD, XENT, FFWM, RIVE; Shareholders are Encouraged to Contact the Firm
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
Exposures Legal
INVESTIGATION: Halper Sadeh LLP Investigates NLOK, XENT, NWHM; Shareholders are Encouraged to Contact the Firm
From Halper Sadeh LLP
Via AccessWire
Topics Fraud
Exposures Legal
Benzinga's Top Ratings Upgrades, Downgrades For August 12, 2021
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021
Via Benzinga
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Via Benzinga
Exposures COVID-19
INTERSECT ENT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intersect ENT - XENT
From Kahn Swick & Foti, LLC
Via Business Wire
Why Intersect ENT Shot 12% Higher on Friday
Via The Motley Fool
Intersect ENT Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Intersect ENT, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – XENT
From Halper Sadeh LLP
Via Business Wire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Medtronic Expands Its ENT Portfolio With Intersect ENT Acquisition For $28.25/Share
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Intersect ENT: Q2 Earnings Insights
Via Benzinga
Intersect ENT Reports Second Quarter 2021 Financial Results
From Intersect ENT, Inc.
Via Business Wire
U.S Nationwide Commercial Availability of the VenSure™ Balloon Sinus Dilation System and Cube™ Navigation System Highlight Intersect ENT’s Continued Commitment to Providing Innovative, Solutions for Patients with Chronic Rhinosinusitis
From Intersect ENT
Via Business Wire
Earnings Scheduled For August 6, 2021
Via Benzinga
Intersect ENT Sees Q2 Sales Lag Wall Street Estimates; Raises $60M In Debt Funding
Via Benzinga
Intersect ENT to Report Second Quarter 2021 Financial Results on August 6
From Intersect ENT, Inc.
Via Business Wire
Intersect ENT Announces Preliminary Revenue for Second Quarter of 2021 and Closing of $60 Million Term Loan
From Intersect ENT, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 24, 2021
Via Benzinga

Frequently Asked Questions

Is Intersect ENT, Inc. - Common Stock publicly traded?
Yes, Intersect ENT, Inc. - Common Stock is publicly traded.
What exchange does Intersect ENT, Inc. - Common Stock trade on?
Intersect ENT, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Intersect ENT, Inc. - Common Stock?
The ticker symbol for Intersect ENT, Inc. - Common Stock is XENT on the Nasdaq Stock Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.